期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 218, 期 6, 页码 -出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20182163
关键词
-
资金
- Jackson Laboratory
- National Institutes of Health [CA195712]
- Department of Defense [W81XWH1710010]
- Merck
- U.S. Department of Defense (DOD) [W81XWH1710010] Funding Source: U.S. Department of Defense (DOD)
Metastasis of melanoma significantly worsens prognosis; the CD33+CD11b+CD117+ myeloid cells could serve as a potential biomarker and therapeutic target for metastatic melanoma.
Metastasis of melanoma significantly worsens prognosis; thus, therapeutic interventions that prevent metastasis could improve patient outcomes. Here, we show using humanized mice that colonization of distant visceral organs with melanoma is dependent upon a human CD33+CD11b+CD117+ progenitor cell subset comprising <4% of the human CD45+ leukocytes. Metastatic tumor-infiltrating CD33+ cells from patients and humanized (h)NSG-SGM3 mice showed converging transcriptional profiles. Single-cell RNA-seq analysis identified a gene signature of a KIT/CD117-expressing CD33+ subset that correlated with decreased overall survival in a TCGA melanoma cohort. Thus, human CD33+CD11b+CD117+ myeloid cells represent a novel candidate biomarker as well as a therapeutic target for metastatic melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据